Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease
Trial details
- Registry ID
- NCT02914561
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as GLPG0634; GS-6034; Jyseleca®
| No regulatory events match this view.This does not mean no FDA events have occurred. |